Background: Globally, cardiac rehabilitation (CR) is recommended as soon as possible after admission from an acute myocardial infarction (MI) or revascularisation. However, uptake is consistently poor internationally, ranging from 10% to 60%. The low level of uptake is compounded by variation across different socioeconomic groups. Policy recommendations continue to focus on increasing uptake and addressing inequalities in participation; however, to date, there is a paucity of economic evidence evaluating higher CR participation rates and their relevance to socioeconomic inequality. Methods: This study constructed a de-novo cost-effectiveness model of CR, utilising the results from the latest Cochrane review and national CR audit data. We explore the role of socioeconomic status by incorporating key deprivation parameters and determine the population health gains associated with achieving an uptake target of 65%. Results: We find that the low cost of CR and the potential for reductions in subsequent MI and revascularisation rates combine to make it a highly cost-effective intervention. While CR is less cost-effective for more deprived groups, the lower level of uptake in these groups makes the potential health gains, from achieving the target, greater. Using England as a model, we estimate the expenditure that could be justified while maintaining the cost-effectiveness of CR at £68.4 m per year. Conclusions: Increasing CR uptake is cost-effective and can also be implemented to reduce known socioeconomic inequalities. Using an estimation of potential population health gains and justifiable expenditure, we have produced tools with which policymakers and commissioners can encourage greater utilisation of CR services.
Introduction
As the leading cause of death globally, heart disease was associated with an estimated 9.43 million deaths in 2016. 1 The links between heart disease, the obesity epidemic and physical inactivity are well established, [2] [3] [4] [5] and are the primary reason for the risk of heart-disease-related death being almost three times greater in high-income countries than low-income countries. 1 As a result, cardiac rehabilitation (CR), which is a multi-component complex intervention, has been at the forefront of attempts to reduce the impact of heart disease on population health in the developed world. 6, 7 Previous Cochrane 8, 9 and clinical reviews 10 have found that there are clear benefits from CR, which the National Institute for Health and Care Excellence (NICE) in England have indicated as being highly cost-effective. 11, 12 As a result, in their latest guidance issued in 2013, NICE recommended that CR is offered as soon as possible after admission for acute myocardial infarction (MI), 12 a decision mirrored elsewhere in the world. 6, 7, 13 Despite the guidance by NICE and similar initiatives in Europe, Canada and the US to improve the rate of uptake, the proportion of patients accessing CR remains stubbornly below stated national targets, such as 65% in England and 70% in the US, 6, 14 with uptake ranging from 10% to 60% globally. 10, 15 The problem of sub-optimal uptake is compounded by poorer uptake in more deprived groups, further compounding inequalities in health. 16 A number of interventions have been proposed to increase CR uptake rates, including improving the education of health professionals 17 and improving the accessibility of rehabilitation centres and home provision. 18, 19 However, little consideration has been given as to the level of expenditure that can be justified while maintaining the cost-effectiveness of the CR programme, or whether interventions should be stratified by deprivation group to reflect the role of deprivation in uptake and capacity to benefit.
To address these gaps in the evidence, this study explores three key aspects: (1) determine if CR can be considered cost-effective given the contemporary evidence on its effectiveness; (2) establish what economic analysis can tell us about how much can be spent on interventions to increase uptake, while maintaining cost-effectiveness; and (3) explore the role of deprivation in reducing both the potential to engage with CR and to gain from it.
Methods
In order to estimate the cost-effectiveness of CR, a scoping review of the current evidence relating to its effectiveness and cost-effectiveness was undertaken. The 2016 Cochrane review 8 was identified as the most complete contemporary systematic review of the effectiveness evidence, exploring the impact of CR on four key aspects: the rate of repeat MI; revascularisation as either percutaneous coronary intervention (PCI) or coronary artery bypass grafts (CABG); hospitalisation; and mortality (cardiovascular and all-cause). Incorporating 63 trials and 14,486 patients with heart disease, the review represents an authoritative overview of the findings of the CR literature. Details are published elsewhere, 8 but in brief the review found that CR led to a statistically significant reduction in cardiovascular mortality (but not total mortality as per the previous Cochrane review 9 ) and hospitalisation, but an insignificant decrease in the rate of MI and revascularisation.
A recent systematic review of cost-effectiveness studies of CR identified a limited number of relevant studies. 20 Furthermore, while an economic evaluation was conducted to inform the NICE guidelines (CG172 and CG48) following MI, 11, 12 it was not appropriate to replicate the original model as it fails to reflect current thinking around the mechanisms of CR. 8 Furthermore, up-to-date costings and evidence is now available, making the results of the NICE guidelines model inappropriate for current decision-making. As a result, a de-novo model, taking account of the modern era of cardiology, was constructed to fully incorporate the findings of the Cochrane review into an economic evaluation framework.
The population
We consider a patient population in keeping with the core studies in the CR field: the latest Cochrane review; the BHF National Audit of CR (NACR); the latest NICE guidelines on CR; and a European-led, modern era, review of CR. 8, 12, 21, 22 This constitutes all adults who have had a recent ST-elevation or non-ST-elevation MI (STEMI or non-STEMI), PCI or CABG, consisting of an estimated 121,499 patients in England in 2015/16. 21 The modelled cohort has a starting age of 67 (the age at which they are eligible for CR) and a maleto-female ratio of 0.70. 21 
The intervention
In broad terms, CR services are defined as 'comprehensive, long term programmes involving medical evaluation, prescribed exercise, cardiac risk factor modification, education, and counselling', 10 therefore constituting a range of potential modalities tailored to the patient's needs rather than a single fixed intervention. The 2017 NACR found the majority of patients underwent a group-based programme (between 70% and 85%) with a spread across the other modes of delivery, such as home-based. Although there is significant variation in terms of intensity, frequency and duration of CR within the mode of delivery, 20, 21 recent observational studies of routine practice suggest that patient benefit is equivalent following group-based or home-based CR. [23] [24] [25] Our approach to the mode of intervention was to be inclusive as per the Anderson review 8 and the NICE guidance, 12 incorporating the full definition of CR, as is known to occur in clinical practice. 21 
The model
Decision modelling can be used as a quantitative means of combining evidence from a variety of sources to inform a particular decision problem. 26 In this case, the Cochrane review alongside other sources of evidence, detailed in the following and in the Supplementary Appendix, are used within a Markov model structure to explore the impact of CR on the long-term health of patients and the costs to the NHS, stratified by patient deprivation. Figure 1 provides an overview of the model. As a starting point, all patients are assumed to inhabit the 'well' state, the point at which after their first MI and/ or revascularisation, they will begin CR if it is available. Due to the availability of CR at this point in the pathway only, we will not consider events prior to this point. We create two realisations of the potential patient pathway: one where CR is available and the patient undertakes it, and one where it is not available. In both realisations the patient can experience the same possible transitions, as shown in Figure 1 , but the probability of them experiencing these is different in the presence of CR, as informed by the Cochrane Review 8 and national audit estimates. 21 The model allows patients to stay in a 'well' state, experiencing no further cardiac events, or to require admission to hospital. During a hospitalisation, a patient can require no further care and return to the well state, or they can be identified as having had a MI, and can then go on to have a PCI or CABG for the MI; alternatively, they can require revascularisation (PCI or CABG) for a non-MI event. From all states, patients can die from cardiovascular disease (CVD)-related events, other causes or, in the case of revascularisations, surgical adverse events. The structure of the model is driven by the Cochrane analysis, designed around the meta-analyses conducted.
Parameter estimation
The full list of parameters, which inform the base-case analysis, is supplied in the Supplementary Appendix. The Cochrane review 8 provided the informative evidence for many of the parameter estimates required for the model. We re-estimated the meta-analyses conducted in the Cochrane review in order to provide the most flexibility to inform the decision model, which requires transition probabilities rather than the risk ratios estimated in the review. Other model parameters were estimated from other published sources and data requests made to the NACR.
The NHS reference costs were used as the main source of unit cost evidence, supplemented with estimates from published literature. Patient quality of life was modelled using the utilities generated in the Lewis et al. 27 analysis, applied as decrements to an age-adjusted profile of 'normal' population quality-of-life scores. 28 The model is constructed in keeping with best practice as reported in the NICE Methods Guide, 29 including the use of a discount rate of 3.5% for both costs and outcomes, a lifetime analytical horizon and the use of an NHS and personal social services perspective combined with patient health outcomes measured in terms of quality-adjusted life years (QALYs).
To estimate the additional expenditure justifiable to increase the rate of uptake while remaining cost-effective, we use an estimate of the marginal productivity of the NHS of £12,936/QALY as reported by Claxton et al. 30 This was used to estimate the point at which increases in population health from an increase in CR uptake would no longer be worth the opportunity cost to the NHS of funding them in place of other activities.
The role of completion
In addition to issues of low level of uptake of CR, a number of patients who commence the programme do not finish it, estimated as 24.6% using the latest NACR data request. The variation in CR programmes means that the impact of a patient failing to complete can have different impacts. For example, under a cohort programme, where a group conducts the programme as a single class, it is not possible to replace someone who drops out during the course and, thus, the place is lost. In contrast, under a rolling programme where patients join and complete the programme on a continuous basis, the drop-out can be replaced by another patient with only the loss of a few sessions.
To ensure a conservative approach to estimating the cost-effectiveness of CR, our base-case analysis assumes that all patients who fail to complete a CR programme entail the full cost of the programme to the NHS but receive none of the health benefits.
Incorporating uncertainty
To explore the role of uncertainty in our model, we conducted probabilistic sensitivity analysis (PSA), 26 whereby distributions are fitted to all relevant model parameters to reflect the range of possible mean values for the cohort. The informative distributions used are detailed in the Supplementary Appendix. Such an approach explicitly incorporates the uncertainty reported in the Cochrane review regarding the effectiveness of CR. By repeatedly sampling from the informative distributions, the accumulated impact of the combined uncertainty can be reported. The results of this resampling is reported in terms of both the probability of CR being cost-effective as well as the impact of the uncertainty on the justifiable expenditure to increase CR uptake.
Incorporating the impact of deprivation
The role of social inequality and deprivation on cardiovascular health [31] [32] [33] and CR engagement [34] [35] [36] is well documented. To consider the role of deprivation both on the cardiovascular health of patients as well as their propensity to engage with CR, we modelled the correlation between a number of key parameters and an index of multiple deprivation (IMD). The parameters included were selected through a pragmatic search of the literature based on the identification of areas where deprivation was expected to have an impact a priori. The values incorporated in the model are given in Table 1 , with all odds ratios indexed against IMD3 for modelling purposes. As expected, the identified a priori evidence suggests that the level of uptake and completion are worse in more deprived groups (IMD levels 1 and 2), who also experience poorer health outcomes, both for CVD and all other health concerns.
Results

Cost-effectiveness of the CR programme
The cost-effectiveness results generated by the model are presented in Table 2 , reporting the following: the total discounted costs and benefits for both CR and no CR strategies, the incremental cost-effectiveness ratio (ICER) and the probability of CR being cost-effective at a threshold value of £12,936/QALY, all stratified by IMD status.
Across all IMD categories CR is associated with greater total discounted costs and QALYs than no CR, resulting in an ICER that would conventionally be considered highly cost-effective with high certainty, as the mean ICERs are below £3500/QALY for all IMD groups, and the probability of cost-effectiveness is 99.6%. The results also demonstrate the impact of socioeconomic inequality on the cost-effectiveness of CR. The poorer quality of life, life expectancy and recurrence rates of the more deprived results in the deprived cohort's baseline expected QALYs much lower, 3.80 QALYs in IMD1 compared to 5.12 in IMD5, while their poorer completion rates make their propensity to gain under the current CR system less incremental QALYs of 0.22 compared to 0.32. Scatter plots presenting the probabilistic simulations for each of the IMD groups, and a table of results under the assumption that completion rates are 100%, are provided in the Supplementary Appendix.
The benefit and justifiable cost of reaching 65% uptake Table 3 provides estimates of the annual total health gains (in terms of QALYs) from achieving the 65% uptake target (assuming current rates of completion), alongside the justifiable expenditure to achieve the target, stratified by IMD. The total population health gain was calculated by combining the increased uptake required to achieve the target, the estimated size of the eligible population per year and the QALY gain per person starting CR, as reported in Table 2 . The total justifiable expenditure represents an estimate of the additional cost that could be spent on a CR programme while maintaining its cost-effectiveness. Table 3 shows that while the potential health gains per person, and, therefore, the justifiable expenditure to achieve them, are less in the more deprived groups, as they have the greatest required increase in uptake to achieve a 65% target, the total justifiable expenditure to achieve them is similar in the less deprived groups. The exception is the IMD5 group who, in spite of their large potential to gain from CR, have a relatively low total justifiable expenditure (£10.7 m) due to their significantly higher current uptake greatly reducing the total gain from achieving the target. The total justifiable expenditure of £68.4 m across all groups provides an estimate of the maximum annual expenditure that could be justified if intervention was able to increase uptake to 65% in all IMD groups.
Alongside estimating the probability of CR being cost-effective, the PSA simulations can be used to show the impact of parametric uncertainty on the estimate of total justifiable annual cost to reach a 65% uptake target, as shown in Figure 2 . The figure shows NACR: National Audit of cardiac rehabilitation; CR: cardiac rehabilitation; QALY: quality-adjusted life years. *The numerator for this estimate of uptake is calculated using only those programmes that upload their data to NACR, averaged across 2015-2018; we assume the same rate of uptake in these programmes as those who do not upload their data to NACR. This assumption is consistent with current NACR reporting. the cumulative distribution functions of total justifiable cost to achieve the target, stratified by IMD group. For IMD1-4, roughly 90% of the simulated values occur under £26.0 m, highlighting the large variation in the estimate; for IMD5, this is under £18.0 m. The distribution of IMD5 lies apart from the others due to the lower required increase in uptake to reach a 65% target, despite the relatively greater justifiable expenditure per person.
Summing across all IMD groups gives a total justifiable expenditure of £68.4 m if all groups achieve the target, with a 95% confidence interval of £44.1 m to £94.6 m. If a 65% target was achieved, our analysis suggests this would result in a reduction of roughly 21,000 hospital admissions and 8500 deaths averted over 10 years. If a more optimistic target of 85% was set, there would be a reduction of almost 49,000 admissions over 10 years, and 19,500 fewer deaths over 10 years.
Discussion
We find that the low cost of CR and the potential for reductions in subsequent MI and revascularisation rates combine to make it a highly cost-effective intervention across all IMD groups. While the per-patient lifetime costs to the NHS of providing CR to more deprived groups is greater than those that are less deprived, and the expected QALY gains less, the lower level of current uptake in the more deprived groups makes the potential health gains from achieving a 65% target greater, and, thus, the total justifiable expenditure.
The main strength of this analysis is that this is the first economic evaluation of CR to incorporate the findings of the Cochrane review, alongside the incorporation of the role of deprivation on both cardiovascular health and engagement with CR. This framework provides estimates of justifiable expenditure which can facilitate decision makers to invest in policies to increase CR uptake.
However, the analysis also has a number of weaknesses, primarily the failure to reflect different CR programmes and the potentially restrictive structure of the model. Ideally, the economic evaluation would incorporate the range of different CR programme types to explore the relative cost-effectiveness of different approaches. However, the nature of the Cochrane review, which did not stratify by CR type, in addition to the recommendation that CR is flexible to patient preferences, made the incorporation of multiple programme types into the analysis both infeasible and potentially uninformative to decision makers. Furthermore, recent analyses suggests that outcomes and completion rates do not vary substantially between different modes of delivery. [23] [24] [25] Similarly, the structure of the model is potentially an over-simplification of the post-event patient pathway, failing to explicitly reflect the full range of events -for example, stroke and long-term non-fatal disability. However, the use of the Cochrane review to inform the parameter estimates limited the potential to incorporate a wider set of explicit patient events.
The most valuable element of this analysis is its ability to be used as a framework to demonstrate the business case for investment in interventions which increase the uptake of CR, particularly those which address the issue of inequality of uptake. 21 Furthermore, by demonstrating the impact of uncertainty around the patient pathway, we allow decision makers to understand how the estimate of justifiable expenditure to reach a 65% target can be tailored to their aversion to risk.
Whilst the probabilistic analysis demonstrates that CR is highly likely to be cost-effective, with a probability of being cost-effective of almost 100% for all IMD categories, the uncertainty in the parameter estimates results in a wide distribution in terms of the justifiable expenditure to increase CR uptake. Therefore, while there is little value in further research in terms of demonstrating the cost-effectiveness of CR, such research would be informative to the business case of interventions seeking to increasing uptake to ensure efficient spending.
Finally, the analysis focus is on increasing CR uptake; however, there is the potential for the expenditure on CR programmes to be wasted if patients do not complete the programme. As a result, further discussion and research should be conducted to explore the role of non-completion on impacting the effectiveness and cost-effectiveness of CR, and the propensity of interventions to increase completion rates. 
Conclusion
We conclude that CR, as it is currently delivered, is cost-effective across all IMD groups due to its low cost and high effectiveness in improving cardiovascular outcomes, as demonstrated by the Cochrane review. Furthermore, we show that there is a clear business case for spending money on incentives which increase CR uptake to a 65% target, stratified by IMD, with a justifiable expenditure of £68.4 m per year. Our analysis does, however, demonstrate that there is significant uncertainty around this justifiable expenditure, which originates from the uncertainty in the Cochrane review estimates of the effectiveness of CR. However, the lowest 95% confidence interval of the total justifiable expenditure is still £44.1 m, demonstrating the large potential benefit of increasing CR uptake, regardless of the significant uncertainty.
